Bioquell and COVID-19
Learn more about Bioquell and Ecolabs response, our solutions, the latest news, and key information about the COVID-19 pandemic.
BIOQUELL UK LTD TO HIGHLIGHT SUITABILITY OF ‘WORLD FIRST’ QUBE ASEPTIC WORK STATION FOR CAR-T, GENE AND CELL THERAPY The only isolator to offer built in Bioquell Hydrogen Peroxide Vapour technology for rapid decontamination, reduced risk and major cost benefits Bioquell UK Ltd – one of the leading global experts in reducing the risk of […]
Read MoreBIOQUELL SHORTLISTED FOR UK STOCK MARKET AWARD Bioquell UK Ltd (www.bioquell.com; tel: +44 (0) 1264 835835) – one of the leading global experts in reducing the risk of bio-contamination in the life science, healthcare and pharmaceutical markets – has been shortlisted in the highly competitive Best Health Care & Pharmaceutical PLC category of the […]
Read MoreThe latest generation isolator was installed at the National Institute for Bioprocessing Research and Training (NIBRT) based in Dublin, Ireland, this February. The Bioquell Qube, a flexible aseptic workstation, is now up and running to assist with continual professional development at this leading institute for the life sciences industry. From order to installation, it only […]
Read MoreThe Polish subsidiary of a major international generics and specialty pharmaceutical manufacturer has chosen a Bioquell Qube M-11 system to provide the ideal environment for carrying out its product sterility testing. Previously, the quality department had been performing sterility testing utilising a laminar flow system and cleanroom for product protection. The critical nature of such testing and the […]
Read MoreA multi-national vaccine manufacturer approached Bioquell in order to perform a Biodecontamination within its FDA approved facility. The facility itself, some 5,500 cubic meters, was treated as a single Biodecontamination enclosure with the entire process completed within 30 hours. After a successful deployment of the project,the customer contacted Bioquell wishing to establish an industry leading […]
Read MoreBioquell was approached by a multinational bio-pharmaceutical company to provide remediation planning in case of a breach of sterility or contamination event across their 4 European sites. A Bioquell specialist visited each production site in turn in order to establish an emergency Hydrogen Peroxide Vapour decontamination protocol to be implemented in the event of a contamination incident. Working […]
Read MoreA team from St Jude’s Hospital in Memphis, Tennessee have identified a genetic mutation within a VRE bacteria that appears to confer wide ranging antibiotic tolerance, particularly in a biofilm presentation. Published in January’s edition of mBIO (American Society for Microbiology) the research findings came about due to an extremely difficult case of bacteraemia in a 6 […]
Read MoreCandida auris is an emerging pathogen with a high level of resistance to standard anti-fungal treatments. It is a causative agent of candidiasis, which when systemic (i.e. within the bloodstream) can result in high levels of mortality. The US CDC released guidance last year on the reporting, diagnosis, treatment and control of C.auris. On the 16th February, […]
Read MoreLeading Biodecontamination experts Bioquell warmly welcomes the latest publication by the HSE highlighting the timescale for hydrogen peroxide-based biocides to be compliant. The HSE Biocides e-Bulletin 22 September 2016 is entitled ‘Active Substance Approval Reminder’ and summarises all of the key dates for the evaluation of hydrogen peroxide in Product Types 1, 2, 3, 4, […]
Read More